Abstract. G protein bg subunits are central participants in G protein-coupled receptor signaling pathways. They interact with receptors, G protein a subunits and downstream targets to coordinate multiple, different GPCR functions. Much is known about the biology of Gbg subunits but mysteries remain. Here, we will review what is known about general aspects of structure and function of Gbg as well as discuss emerging mechanisms for regulation of Gbg signaling. Recent data suggest that Gbg is a potential therapeutic drug target. Thus, a thorough understanding of the molecular and physiological functions of Gbg has significant implications.
G protein b subunits were first discovered as components of G proteins almost 30 years ago. Despite enormous advances since then, there remain multiple emerging and unanswered questions about the fundamental details of the biochemical roles for Gbg in GPCR-dependent G protein activation, as well as questions about broader roles in novel signaling mechanisms, physiology and pathophysiology. Heterotrimeric G proteins consisting of multiple isoforms of distinct Ga, b and g subunits mediate the actions of a wide variety of cell surface receptors [1 -3] . Receptors catalyze exchange of tightly bound GDP for GTP on the a subunit in a process that requires the complete heterotrimer. In the classical model for G protein signaling, binding of GTP results in activation of the G protein and dissociation of the Ga subunit from the Gbg subunits (Fig. 1A) . In recent years, a variety of reports have suggested additional modes of activation that could either add complexity to the classical model or represent entirely independent mechanisms for heterotrimeric G protein regulation [4 -10] . Whatever the mode of G protein activation, the Ga and Gbg subunits both interact with effector molecules, such as phospholipases and ion channels, in a manner that leads to their activation. Gbg does not have a catalytic site and thus acts as a modulator of G protein signaling through regulated protein-protein interactions. The list of molecules that have been reported to bind to Gbg continues to grow. While great progress has been made in the understanding of Gbg structure and function, fundamental mechanisms for molecular recognition and effector regulation by Gbg have yet to be fully elucidated. Additionally, how all these interactions are coordinated to mediate various G protein signaling processes in cells and tissues is not entirely clear. In this review we will discuss general background concerning Gbg structure and function with an emphasis on new and emerging mechanisms and approaches for study-ing Gbg signaling. These new data are leading to a greater understanding of how Gbg functions at a mechanistic level and at a coordinated physiological level in cells and tissues. Together, this information could establish a basis for development of future therapeutic interventions.
General structure of the Gbg subunits
The first high resolution structures of the Gbg subunits arose from X-ray crystal structures of G protein heterotrimers elucidated by the Sprang group [11] , and independently by Paul Siglers group [12] . Subsequently, the structure of the Gbg dimer alone was solved [13] . The Gb subunits fold into a prototypical bpropeller comprised of four-stranded b sheets forming each of the seven blades of the propeller (Fig. 1B) . The first 57 -70 amino acids N-terminal to the b-propeller comprise an a-helical domain that forms a tight coiled-coil interaction with the g subunit. The most highly conserved regions of the protein are the b sheets of the propeller and variable loops connect the b strands. Two independent structural elements of the Ga subunits interact with different regions of Gbg. The Ga N-terminal a helix (yellow, Fig. 1C ) interacts with the side of the b propeller at blade 1. The Ga switch II region that undergoes conformational changes upon GTP binding interacts with the top of the b propeller (dark blue helix, Fig. 1C ). In the structures of Gbg that have been solved there is very little difference in overall structure, with and without bound Ga or other binding partners [13 -15] . An exception is a structure of Gbg bound to phosducin showing a movement of blades 6 and 7 of the b propeller creating a cavity between these two blades [16] . These movements have not been seen in other structures of Gbg [15] and their significance remains to be determined. The apparent lack of significant conformation changes of the Gbg subunit upon G protein activation has led to the concept that Gbg activity, with respect to downstream signaling, is regulated by the mode of Ga subunit binding, with activation-dependent changes in Ga subunit conformation leading to uncovering a signaling surface on Gbg [1] . A current debate concerns whether this involves subunit dissociation or subunit rearrangement.
Synthesis and Trafficking of Gbg
G protein bg subunits are membrane bound proteins that had been suggested to exist almost exclusively on the plasma membrane (PM) tethered to the membrane through post-translational modification. Recent data has led to significant insight into how G protein subunits are synthesized, assembled, processed, and targeted to membranes. A comprehensive review of G protein subunit assembly and trafficking has recently been published [17] , but key points relevant to Gbg assembly and trafficking will be summarized here. Gb and g subunits have no transmembrane hydrophobic domains and are synthesized The G protein cycle. The Ga subunit bound to GDP interacts with the Gb subunit with two contacts involving the Nterminal domain and the GTP binding domain. This is the inactive resting state. This complex is a substrate for the activated GPCR (R * ) which catalyzes an increase in the dissociation rate of GDP from the Ga subunit leading to the nucleotide free Gabg complex. This complex is very short lived in the cell where high concentrations of GTP in the cell bind to the empty nucleotide binding site to drive a conformational change in the Ga subunit. This conformation change leads to the active GaGTP subunit, perhaps separated from signaling competent free Gbg subunits. The Ga subunit has the intrinsic capacity to hydrolyze GTP to GDP, allowing reassembly with Gbg to return to the resting state. Regulators of G protein signaling (RGS proteins) can bind to Ga and enhance the rate of GTP hydrolysis. Pertussis Toxin (PTX) modifies the G protein a subunit and prevents interactions of the GaGDPbg heterotrimer with R * . Also shown are myristoyl and isoprenoid lipid groups at the Ga N-terminus and Gg C-terminus respectively. (B) Ribbon diagram representing the three dimensional crystal structure of the Gbg subunits. The blades of the propeller are numbered as in Wall et al. [11] . The Gb N-terminal helix is in red and forms a coiled coil interaction with the Gg subunit in blue. (C) Ribbon diagram of the G protein heterotrimer with the Gbg subunit rotated 90 o relative to B. The Ga N-terminus is represented as a yellow helix and the Ga Switch II region is in dark blue.
in the cytoplasm. This process has recently been shown to require specific chaperone proteins. Two chaperones are involved in proper folding and stabilization of the newly synthesized Gb subunit. The CCT1 (also known as TRiC) chaperonin complex binds newly synthesized Gb but not Gg and is required for folding into the seven bladed propeller structure [18] . Phosducin like protein (PhLP) appears to act as a co-chaperone with CCT, regulating CCT mediated folding of Gb [19] . Once folded, CCT dissociates and PhLP remains bound until assembly with Gg [20] . A potential chaperone specific for Gg subunits has also been recently identified as Dopamine Receptorinteracting Protein 78 (DRiP78). DRiP78 binds to Gg and PhLP and may be required for Gbg assembly [21] . DRiP78 is localized to the Endoplasmic Reticulum (ER), suggesting that some aspects of the initial assembly process of Gg with Gb could occur on the ER.
Once assembled, the Gg subunit is processed at the Cterminus to attach an isoprenoid moiety. Gg has signal sequences that direct prenylation with either a farnesyl or geranyl-geranyl moiety. The first step in the Cterminal processing reaction is covalent attachment of the isoprenoid group to a cysteine that is four amino acids from the C-terminus by either geranyl-geranyl or farnesyl transferase. Once modified with lipid the Gbg complex is targeted to the ER, where a protease, rasconverting enzyme (Rce1) removes the C-terminal three amino acids from the Gg subunit. Isoprenyl cysteine carboxy methyl transferase (Icmt) catalyzes carboxy-methylation of the C-terminus of Gg to yield the fully modified subunit. Assembly with Ga may also occur on the cytoplasmic surface of the ER prior to trafficking to the PM through an unknown mechanism. Assembly with Ga is important for PM targeting of Gbg. It was previously thought that geranyl-geranylation of Gg would be sufficient for PM targeting, but expression of Gbg alone leads to localization to intracellular membranous structures, primarily ER. However, when coexpressed with Ga, Gbg localizes primarily to the PM. It has been proposed that Ga lipid modification provides an additional signal that is required for efficient PM targeting of both Ga and Gbg [22] . Recent data indicates that once Gbg is fully processed it can translocate to intracellular membranes. Initial work by Berlot and colleagues examined trafficking of Ga s b 1 g 7 complexes after activation by the b2AR [23] . Here, the receptor and the G proteins internalize but segregate to different intracellular compartments upon stimulation with isoproterenol. The G protein Ga and Gbg subunits initially show diffuse cytoplasmic distribution followed by colocalization on intracellular vesicles distinct from bAR containing vesicles. Subsequent work by others has suggested GPCR-activation results in translocation of fluorescently tagged G protein g subunits or tagged b subunits to intracellular membranes such as the Golgi or ER [24] . Distinct families of Gg subunits were found that translocate, whereas other families do not [25] . For example it was found that g 1, 5, 9, 10, 11 and 13 support M2 receptordependent translocation, whereas g 2, 3, 4, 7, 8 and 12 do not [26] . Differences in translocation appeared to correlate with specific sequences in the C-terminus of Gg. These findings are intriguing and suggest specific functional roles for Gg subunit subtypes although the role of the translocation remains to be defined.
G protein b and g subunit subtypes
Five different Gb subunit and 12 different Gg subunit genes have been identified in the human and mouse genomes [27] . The Gb 1 -4 subunits share greater than 80 % amino acid sequence identity compared to 50 % identity for Gb 5 . There is significantly lower identity amongst the g subunit subtypes. These different subunit subtypes can pair to form unique Gb x g x combinations. The functional significance of the diversity of individual Gbg subunit combinations is not well understood. Interpretation of phenotypes resulting from knockout of individual Gbg subunits is complicated by the fact that Gbg participates in multiple, integrated functional interactions with receptors, Ga subunits, and effectors. Thus, the resulting phenotypes can be difficult to attribute to a specific functional interaction. Nevertheless, there is evidence from knockout studies to suggest that specific Gbg subtypes interact with particular GPCRs. Ribozymedirected Gg 7 subunit depletion impaired b-adrenergic receptor signaling but not signaling by another Gs coupled receptor, PGE 1 [28] . Genetic deletion of specific g subunits in mice results in specific phenotypes. For example, deletion of Gg 7 resulted in distinct behavioral changes associated with specific loss of cAMP production in the striatum [29] , and deletion of Gg 3 results in changes in metabolism resulting in resistance to a high fat diet [30] . In both of these cases loss of the specific Gg subunits also resulted in a loss in specific Ga expression, indicating roles for specific Gabg combinations in these phenotypes.
One instructive example comes from a recent study of Gg functions in the Arabidopsis thaliana plant system. In this plant and other species there is one Ga subunit, one Gb subunit, and two Gg subunits that share approximately 50 % amino acid identity [31 -34] .
Knockout and overexpression of these two Gg subunits allowed for a relatively simple dissection of the functional significance of the two Gg subunit isoforms. In this system, many of the functional effects appear to be mediated by Gbg. For example, Gb plays a specific role in plant pathogen resistance and knockout of A. thaliana Gg 1 increased susceptibility to infection with a pathogenic fungus, while Gg 2 deletion had no significant effect on this function [35] . Similar specificity was seen with other processes involved in seed germination and root development. Thus in this relatively simple G protein system, clear, distinct roles are observed for different Gg subunits. The mammalian system is obviously much more complex with many different Gg subunits, where many detailed experiments will be required to sort out their individual specific functions.
To date, there is no specific, satisfactory mechanistic explanation for the selectivity for different Gbg subunits that is observed in intact cells. Although some selectivity has been observed in some in vitro reconstitution systems, the difference between subtypes is generally not dramatic. An exception is Gbg complexes containing the Gg 1 subunit, which is strictly localized to the retina as part of the transducin heterotrimer. These complexes are generally less potent for activation of effectors such as adenylyl cyclase (AC) and phospholipase C (PLC) [36, 37] and couple less strongly to GPCRs other than rhodopsin. Gg 1 is modified with a 15 carbon farnesyl rather than a 20 carbon geranylgeranyl lipid moiety and some of the difference may result from this, but there is also evidence that there are sequence determinants on Gg 1 that may be partially responsible for differences in efficacy and potency of this subunit [38] . Some other examples of biochemical selectivity for effectors exist but, in general, the differences are not enough to explain the striking differences observed in intact cell systems or in vivo.
Gb 5
Gb 5 is clearly an outlier with respect to sequence homology with other Gb subunits, with 53 % identity to the most closely related Gb subunit. Initial evidence that Gb 5 was a bona fide Gb subunit was its ability to assemble with Gg subunits in transfected cells to activate PLCb2 [39, 40] . Further analysis of purified Gb 5 g 2 complexes revealed that Gg was loosely bound and could be separated from the Gb 5 subunit under non-denaturing detergent conditions where other Gbg combinations are not separable [41, 42] . This Gb 5 g 2 complex was initially proposed to be only capable of binding to Ga q [43] but other workers demonstrated interactions with Ga i/o -GDP [42, 44] . This latter data indicates that Gb 5 has the determinants to direct Gb 5 containing complexes to GDPbound Ga subunits. Siderovski and colleagues were the first to recognize that members of the RGS7 (R7) subfamily of regulators of G protein signaling (RGS proteins) contained regions with significant homology to Gg subunits (ggl domains) and predicted that they could potentially assemble with Gb subunits [45] ( Fig. 2A and B) . Biochemical studies demonstrated that R7 family members could form stable complexes with Gb 5 but not other Gb subunits. In parallel, Slepak and colleagues purified native Gb 5 from bovine retina and identified R7 family members as tightly associated proteins that co-purified [46] . In neither of these studies was Gg found to co-purify or form stable complexes with Gb 5 [47] . This leads to a currently unresolved debate as to whether Gb 5 g x is present in native cells or tissues. It has been suggested that the difficulty in finding Gb 5 g x in native tissues is due to its inherent instability in detergent that is required to extract Gbg subunits from native tissue. A recent study examining Gb 5 complex formation with different Gg subunits in cells using bifluorescence complementation (BiFC) suggests that Gb 5 slightly prefers Gg 2 as a binding partner relative to RGS7. These data suggest that in native tissues, if Gg 2 is present in significant quantity, it would assemble with Gb 5 [44] . On the other hand, other factors such as molecular chaperones may add a level of control to assembly that is not observed in the transfected HEK293 cells.
While the occurrence of this Gb 5 RGS complex is very novel and exciting it is not clear how this complex is regulated and what the functional and physiological role of the complex is in GPCR signaling. Some exciting clues have come with the discovery of a protein, R7BP, that binds to R7 family members [48, 49] . This protein binds to the DEP (for Disheveled, EGL-10, Pleckstrin) homology domain of R7 family members and can regulate the distribution of Gb 5 R7 complexes in cells [48, 49] . R7BP can be palmitoylated near its carboxy-terminus, and regulated palmitoylation depalmitoylation at this site determines the subcellular localization of the R7BP/Gb 5 /R7 complex [49] . Palmitoylated R7BP targets the complex to the PM where it can efficiently inhibit GPCR mediated processes through its RGS domain, while the depalmitoylated form undergoes nuclear-cytoplasmic shuttling that could be involved in regulation of transcription [49, 50] . Interestingly, the DEP domain of R7 is involved in an intra molecular interaction with the Gb 5 subunit in the Gb 5 /R7 complex [51, 52] . In the recently solved crystal structure of Gb 5 -RGS9 complex, the DEP domain, in conjunction with the ggl-DEP linker, occludes the Ga binding site on Gb 5 [52] . 2194 A. V. Smrcka G protein bg subunits Regulatory mechanisms may exist that "uncap" the Ga binding site on Gb 5 to allow productive interactions with Ga subunits for receptor catalyzed nucleotide exchange reactions [53, 54] . For example, R7BP could affect this interaction which could, in turn, affect the activity of the Gb 5 /R7 complex ( Fig. 2B and C [55, 56] . Studies examining muscarinic receptor coupling to Ga o initially suggested that a possible reason for the requirement for Gbg was that Gbg was simply required to target Ga o to the membrane and that, once properly oriented at the plasma membrane, Ga could productively engage the receptor [57] . While this may be part of the requirement for Gbg function in receptor coupling, it does not exclude other mechanisms for promoting coupling and cannot, in itself, explain receptor selectivity for particular Gbg isoforms. Another possibility that is supported in part by structural data is that binding of Ga to Gbg organizes the structure of the Ga subunit such that it is a substrate for receptor interactions. Free Ga i subunits are in a distinct conformation relative to the structures in the G protein heterotrimer [11, 12, 58, 59] . For example, in the structure of Ga i -GDP the amino terminus forms a distinct globular domain that adopts an extended helical conformation in direct contact with Gbg in the Ga i -GDPbg complex [58] . The amino terminus of the Ga subunit is important for engagement of phospholipid membranes through lipid modifications at the N-terminus. Additionally, amino acids in the Ga N-terminus are important for receptor-G protein coupling, suggesting that Gbg may help present Ga in the appropriate conformation to the receptor [60] .
GPCRs also interact directly with G protein bg subunits. A peptide mimic of the third loop of the a 2A adrenergic receptor catalyzed nucleotide exchange on Ga o in a purified system only in the presence of the Gbg subunits [61] . The peptide was directly crosslinked to the G protein b subunit, and the crosslinking site was mapped to the C-terminus [62] .
Other studies have demonstrated direct binding of receptor fragments to Gbg subunits primarily using glutathione S-transferase (GST) fusion protein binding assays. For example, a portion of the C-terminal tail of the parathyroid hormone receptor bound directly to Gbg subunits [63] . The specific Gbg [64] . The data suggest that maintenance of Gbg binding to this loop facilitated recruitment of G protein coupled receptor kinase (GRK) to the receptor. Another point of contact between Gbg and receptors is the C-terminus of the Gg subunit. As discussed earlier, Gg is prenylated at a C-terminal cysteine. This prenyl modification is required for receptor-G protein coupling but, since it is also required for membrane targeting, it is difficult to determine if the G protein coupling requirement simply reflects the need for Gbg to be at the membrane or if it is a direct physical coupling between the receptor and Gg. Evidence for direct physical interactions comes from experiments utilizing prenylated C-terminal peptides from Gg 1 . These peptides inhibit receptor-G protein coupling and alter the activation state of rhodopsin, indicating a direct physical interaction [65] . NMR studies show a specific conformational alteration of the peptide upon receptor activation [66, 67] . In many of the structures of Gbg this region of Gg is disordered, suggesting this region may be conformationally flexible.
Still unanswered is how direct GPCR-Gbg interactions are mechanistically involved in the G protein activation process. This, in part, comes from our current lack of general understanding of the mechanistic details of GPCR stimulated nucleotide exchange. As discussed, some models of receptor activation portray the Gbg subunit as a passive participant that scaffolds Ga at the membrane, while others indicate an active role. Two models that include Gbg as an active participant include the lever hypothesis and the gearshift model. In the lever hypothesis, the receptor has been proposed to engage both Ga and Gbg and pry the two molecules apart by pulling on the N-terminus of Ga, acting as a lever to open up the interface between the switch II region of the Ga subunit contacting the Gb subunit (Fig. 3A) . As the subunits rearrange, the Gb subunit pulls open the nucleotide binding pocket on Ga, enhancing the offrate of GDP [68] . One line of evidence in support of this hypothesis is that mutation of amino acids on Gb that directly interact with Ga switch II prevents Gbdependent Ga activation. In contrast, other data indicates that the Switch II Gb interface can rapidly "breathe" without full subunit dissociation. This model, depicted in figure 4A , is based on evidence that Ga N-terminal interactions and Ga Switch II interactions with Gb are individually weak but the combined bivalent interaction is strong [69, 70] . Peptides and proteins appear to be able to bind to Switch II binding surface on Gb during breathing and cause G protein bg subunit activation without nucleotide exchange on Ga, as discussed in section 6 ( Fig. 4B and C). Since the Ga/bg interactions at these surfaces are weak, they may not be sufficiently stable to pry open the nucleotide binding pocket as the subunits reorient relative to one another in the lever model. The gear shift hypothesis suggests that the receptor increases interactions between the coiled-coil amino terminus of the Gbg complex and the helical domain of Ga, pushing the helical and Ras-like domains of Ga apart to provide an exit route for GDP (Fig. 3B ) [71] . Recent BRET data examining Ga-bg interactions in intact cells demonstrate that some parts of the helical domain of Ga move away from the N-terminus of Gg subunits upon activation, but the region linking the helical and GTPase domains move closer to Gg-N. The authors suggest that these movements, where parts of Gbg and Ga move closer together during the activation process, are most consistent with the gearshift model for G protein activation [6] . In either mechanism, Gbg is intimately involved in the process of nucleotide exchange. For a detailed discussion of these models see Oldham and Hamm [60] . If, in fact, there are direct interactions between receptors and Gbg that are important for the mechanisms of nucleotide exchange and subunit dissociation, it has significant implications for the specificity with which receptors recognize specific Gbg isoforms. If the sole function of Gbg were to serve as a scaffold for Ga, the reported selectivity of receptors for particular Gbg subtypes would be unlikely to have been observed.
Mechanisms for activation of Gbg signaling
In addition to its supporting role in GPCR-dependent Ga interactions, Gbg acts to directly regulate downstream signaling in its own right. The first effector found to be activated by Gbg was the acetylcholineregulated inwardly-rectifying K + channel in atrial myocytes [72] . A key observation in isolated insideout patches from atrial myocytes was that the acetyl choline driven channel activation was independent of soluble second messengers, suggesting that the subunits of the Gi protein could directly activate the channel. This led to attempts to directly activate the channel in excised atrial membrane patches with Gbg and Ga subunits [72, 73] . After considerable controversy a consensus emerged that Gbg subunits are the primary mediators of channel activation through 2196 A. V. Smrcka G protein bg subunits direct binding to the channel [74, 75] . At first, recognition of Gbg as the primary mediator of channel activation was controversial, in part, because Gbg mediating direct downstream functions had not been previously demonstrated, and because precedent with adenylyl cyclase demonstrated that Ga s was responsible for direct stimulation of adenylyl cyclase activity.
Additional support for the idea that Gbg is a signal mediator in its own right came from genetic analysis of the pheromone signaling pathway in yeast, indicating that Gbg is the key activator of downstream signaling from the G protein coupled pheromone receptor [76] . Today, the list of proteins that interact with Gbg has expanded to encompass a large number of targets (Table 1) . In some cases, these are enzymes or channels and it is clear that Gbg-binding has a functional effect on the activity of the target. In the case of ERK, Gbg expression in cells leads to ERK activation, but the direct binding target and the exact mechanism for this activation has not been defined. In many instances the regulation of the target has a clearly documented physiological correlate whereas, in others, the physiological significance of the Gbgtarget interaction is not clear. Overall, however, it is now well established that the Gbg subunits play major roles in mediating downstream signaling from GPCRs and may be as prevalent as those mediated by Ga subunits. When considering how G proteins are activated by GPCRs, it is the Ga subunit that undergoes significant conformational changes upon binding of GTP, suggesting an obvious mechanism for Ga activation. So how can Gbg be "turned on" to propagate a downstream signal? The current model, as discussed earlier, is based on the subunit dissociation model where Ga subunits occlude effector binding surfaces on G protein bg subunits until activated by binding of GTP. The conformational changes in Ga lead to dissociation from Gbg to expose effector interaction surfaces on Gbg (Fig. 1 ). Some evidence for this idea stems from the observation that addition of purified GaGDP to in vitro assays of Gbg-dependent effector activation inhibits effector regulation [72, 77] . Since there is no apparently critical difference in Gbg subunit structure in either the free or heterotrimeric structure, it suggests that G protein activation does not cause alteration of Gbg subunit conformation [11 -13] . A direct test of the hypothesis that a signaling surface on Gbg is covered by Ga involved alanine substitution of amino acids at the Ga subunit-binding surface of the Gb subunit and testing the purified mutant protein for activation of effectors in various in vitro assay systems [78, 79] . Many of these purified Gbg mutants were unable to efficiently regulate effectors. An important conclusion from this analysis was that each effector utilized this surface with both overlapping and unique subsets of amino acids within the Ga subunit binding surface. Complementary studies used a similar mutational approach to map effector binding sites in the blade regions of the Gb propeller and identified amino acids outside the Ga subunit interface important for effector regulation, with some amino acids involved in unique effector interactions [80] . Thus, G protein a subunit activation likely exposes surfaces on Gb that form a core site for effector binding but multiple other Gbg surfaces also participate in effector binding and activation.
Pertussis toxin-sensitive signaling by G protein bg subunits As discussed above, acetyl choline-dependent regulation of the atrial K + channel is now known to be through Gbg binding to the channel. This acetylcholine regulation of the potassium current is inhibited in isolated atrial myocytes by pretreatment with pertussis toxin (PTX) which selectively modifies Ga i family G proteins [81] . Many other processes dependent on Gbg downstream signaling are also inhibited by PTX. For example, GPCR-dependent PLC activation is mediated by pertussis toxin-sensitive and -insensitive mechanisms [82, 83] . The PTX-insensitive pathways are primarily mediated by Ga q -dependent activation of PLCb or pathways involving Rho and PLCe [83 -85] . PTX-sensitive pathways were presumed to be mediated by members of the Ga i family yet purified PTX-sensitive Ga i family subunits were unable to reconstitute activation of PLC. On the other hand purified Gbg subunits were able to activate PLCb isoforms in vitro, albeit at relatively high concentrations compared to typical activation by G protein a q subunits [86 -88] . This suggested that Gbg subunits released from Gi heterotrimers were responsible for PTX-sensitive GPCR-dependent PIP 2 hydrolysis. The model for these and other related systems is that PTXdependent ADP ribosylation of the Ga subunits prevents productive interactions between the heterotrimer and receptors preventing nucleotide exchange and activation of Ga i , keeping Gbg sequestered in an inactive state (Fig. 1A) . Many of the GPCR-dependent physiological processes inhibited by PTX are mediated by Gbg subunits rather than Ga [72, 89 -91] . Fewer examples of PTX-insensitive processes being mediated by the Gbg subunits have been reported but likely exist [92] . Thus, most Gbg-dependent signaling appears to arise from Gi proteins. The apparent specificity of Gbg-dependent signaling for Gi-coupled receptors presents a conundrum in terms of what regulates the selectivity of Gbg-dependent processes. In theory GPCR-dependent activation of any G protein subtype would, upon nucleotide exchange-dependent activation of the Ga subunit, lead to free Gbg that could activate any of the Gbg effectors. Several hypotheses have been proposed to explain the observation that not all GPCRs activate Gbg-dependent signaling processes. 1) Gbg subtypes are specifically associated with particular receptors and G protein a subunits and confer effector activation selectivity. The problem with this hypothesis is that specific Gbg subtypes have not been shown to be selective for particular effectors, so while specific subtypes may be associated with particular receptors; it is not clear how these subtypes would confer selectivity for particular effector pathways. 2) The potency for Gbg subunit dependent activation of effectors is 10 -100 fold lower than for Ga subunit mediated effects (see [86] for example). This suggests that activation of receptors that activate Ga s or Ga q would cause activation of Ga subunit-dependent effectors at levels of G protein activation that would be significantly lower than that required to release enough Gbg to activate a Gbg-dependent effector. So, for example, under conditions required to achieve maximal inositol phosphate release through a G qcoupled receptor, Gbg-dependent processes would [180, 181] P-Rex1 Rac GEF [90] Proteins regulated by Gbg PAK (p21 activated kinase) [182] Raf-1 [183] Dynamin [184] Ras GRF [185] Dbl [186] Btk kinase [187] Tubulin/microtubules [188, 189] Histone deacetylase 5 (HDAC5) [190] P114 RhoGEF [191] RGS4 [192] RGS3 [193] ATP sensitive K + channel [194] Phospholipase D1 [195] IP 3 receptor 1 [196] T type Ca 2+ channels [197, 198] FLJ008 Rac/cdc42 GEF [199] Gbg binding proteins RACK I [200] Group III AGS proteins [4, 131] AGS2 TcTex1 [201] AGS7 Thyroid receptor Interacting Protein (TRIP13) AGS8 KIAA1866 AGS9 Rpn10
Gbg effectors (indirect) MAP kinase [202] PLA 2 [203] 1 Physiological Gbg effectors are those proteins that directly bind Gbg and for which a clear physiologic role for Gbg interaction has been established. Proteins regulated by Gbg are proteins known to bind and have activity regulated by Gbg but for which the physiological role for the interaction has not been established. Gbgbinding proteins are proteins that bind to Gbg but where regulation of an activity has not been demonstrated. 2198 A. V. Smrcka G protein bg subunits not be activated. Since Ga i has a relatively low affinity for AC and G i proteins are relatively abundant, activation of G i coupled receptors could release enough Gbg to achieve significant effector activation. Based on the ideas discussed in the above section, one would still predict that G i coupled receptor-activation would lead to stimulation of many of the effectors listed in Table 1 . Some other ideas that could account for the fact that not all Gbg-regulated effectors are activated by Gi coupled receptors, or other receptor types, include: 1) Tissue specific expression of some of the components provides some constraint, with some effectors expressed relatively specifically in certain tissues. For example, PLCb2 and PI3-kinase g are relatively restricted in expression to monocytic cells, and so would only be activated by GPCRs in these cells, but for other effectors an additional mechanism must exist in cells with multiple GPCRs, 2) Restricting the subcellular location of specific effectors and receptors could impart specificity, 3) Precoupling of receptors G proteins and effectors could confer specificity. For example, GIRK channels have been shown to preferentially form complexes with heterotrimers containing specific Ga i subunits and, while Ga subunits do not regulate channel activation, they do bind directly to the channel [93, 94] . If particular Ga subunits provide a docking surface for Gbg targets this could control specificity for specific Ga subunit subtypes [95] , 4) Simultaneous activation of GPCRs with other receptors could lead to availability of Gbg in concert with other cellular signals such as phosphorylation, providing a coincidence detection mechanism for activation of specific effectors.
Effector recognition by Gbg
The targets listed in Table 1 that are recognized by Gbg comprise a diverse array of molecules, many of which are unrelated in terms of structure and sequence. A key question is: What is the nature of molecular recognition that allows Gbg to interact specifically and productively with this diverse array of targets? We will discuss here what is known about the nature of recognition of targets by Gbg based on both direct structural visualization of complexes as well as other biochemical analyses.
Three dimensional crystal structures of Gbg effector complexes: G protein coupled-receptor kinase 2 (GRK2) and phosducin The structure of Gbg has been solved in complexes with Ga subunits, GRK2, and phosducin. Detailed examination of the nature of the interactions supports the general hypothesis that there are common and unique interactions amongst various Gbg targets. This is exemplified best in the co-crystal structure of Gbg and phosducin [14, 16] . Phosducin, a protein first identified as a regulator in the visual signaling system, binds to Gbg and is composed of distinct N and Cterminal domains. Both of these domains are required for productive interactions with Gbg. In the three dimensional structure of the complex, the N-terminus of phosducin associates with an area that overlaps with the GaGDP binding site on the top of the b-propeller, while the C-terminus interacts with the sides of the propeller at blades 1 and 7, a region that does not overlap with GaGDP binding [14, 16] . On the other hand the GRK2-Gb 1 g 2 interface is dominated by interactions at the GaGDP binding site on the top surface of Gb [15, 96] . Interestingly while both phosducin and GRK2 have interactions on the top of the b-propeller at the Ga subunit interface, the modes of interaction are quite different when compared to Ga. For example the GRK2 C-terminus is an extended a helix followed by a short C-terminal loop and it is the loop that interacts with amino acids that also contact the Ga subunit [97] . In the Ga subunit the major contacts with these same amino acids on Gb are from the switch II a helix region and it is the side chains extending from this helix that interact with Gb. Thus, completely structurally distinct motifs from Ga and GRK2 interact with a very similar contact surface on Gb.
Peptide mapping approaches
While crystallography is invaluable in determining protein interaction surfaces, thus far only a limited number of complexes of Gbg with binding partners have been solved by this method. As an alternative, biochemical methods have been used to map effector binding surfaces. A particularly fruitful approach has been to use synthetic peptides from Gbg target molecules. Initial studies in this area identified a peptide from type II adenylyl cyclase that binds to Gbg and blocks Gbg-dependent regulation of multiple, Gbg-regulated effectors [98] . The authors used a molecular modeling and chemical crosslinking approach to identify the binding site for this peptide on Gbg subunits [99, 100] . This binding site mapped to a surface near the Ga switch II-binding site on Gbg subunits and correlates well with the mutagenic mapping analysis of ACII contacts on Gb.
A similar approach was used to map interaction sites between PLCb2 and Gbg. Initial analysis indicated that a protein fragment containing a region of the catalytic domain could block Gbg-dependent PLCb2 activation in transfected COS cells and bound to purified Gbg in vitro [101] . Further analysis with
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Crosslinking to both of these sites was blocked by preincubation by intact PLCb2 or PLCb3 [102] . This indicated that the amino terminus of Gb may function as an effector binding site. Mutagenesis of this site in the Gb subunit to disrupt PLC interactions actually potentiated Gbg-dependent activation of PLCb2, suggesting that binding of this site to PLCb2 inhibits PLC activity [103] . Interestingly, this site plays a role in activation of PLCb2 in the presence of AGS8, as will be described in a later section. The observation that the amino terminus of Gb is an important interaction site in mammals awaits confirmation by other laboratories, but it correlates directly with an effector binding site identified in yeast Gbg subunits [104, 105] . Another approach to examining effector binding surfaces on Gbg and regulation of target molecules has been to use peptides from Gb subunits and test them in effector regulation assays. Peptides from different blades of the Gb propeller were shown to inhibit Gbg dependent regulation of type II adenylyl cyclase [99] or PLCb2 while others stimulated PLCb2 independent of Gbg [106] . This led to the concept that there are distinct effector-binding and signal-transfer surfaces on Gbg. This is based on the hypothesis that blocking peptides correspond to binding surfaces that contribute to the energetics of the Gbg-target binding, but are not involved in altering target activity. On the other hand, activating peptides from Gbg have been proposed to represent signal transfer surfaces that mediate the activation of the effector. This interesting concept remains to be developed further with mutagenic analysis of intact Gbg subunits.
Protein Interaction "Hot Spot" on Gbg Identification of the specific amino acids in Gbg involved in individual target recognition does not explain the molecular basis for Gbg-dependent recognition of diverse effector structures. Various Gbg binding motifs within effectors have been proposed [98] but it has become clear that there is no single consensus sequence or structural motif that mediates binding to Gbg. As an approach to understanding this, Gbg subunits were used as targets in a random peptide phage display screen in an attempt to identify consensus sequences for binding to distinct surfaces on Gbg [107] . Multiple, distinct peptides were identified that apparently bound to the same surface on Gbg based on competition and mutational analysis. This result, where large protein surfaces are subjected to selection in naïve random peptide-binding screens, and only a small portion of the overall surface mediates binding of diverse sets of peptide sequences, is indicative of a preferred protein binding surface [108, 109] . Combining these data with alanine scanning mutagenesis and structural analysis has led to the concept of energetic "hot spots" that provide key energetic residues for binding at a protein-protein interface, but also have intrinsic physical-chemical characteristics that are optimal for mediating multiple protein-protein interactions [109] . Some characteristics of these surfaces are flexibility and the opportunity for mediating multiple types of chemical interactions (ionic, hydrophobic) without strict geometric requirements for binding [110] . In this way a single binding site can accommodate multiple structural and chemical motifs.
Crystallographic determination of the structure of a phage display selected peptide (SIGK) bound to Gbg identified the preferred binding surface as a site corresponding to the Ga subunit switch II binding region on Gb [111] . Alanine substitution of all of the amino acids within 6 of this peptide binding site defined amino acids required for peptide binding. Each of these alanine substituted mutants was then tested for ability to affect binding of other peptides identified in the original phage display screen. Each of the peptides had a unique pattern of requirements for interactions with specific amino acids within the binding site. This demonstrated that the "hot spot" has the inherent ability to bind multiple binding sequences with unique sets of interactions that can be exploited by natural binding partners and suggests a mechanism for Gbg interaction with multiple different sequences and structures.
Mechanisms for effector regulation by Gbg
In the previous section, modes of binding and recognition of targets by Gbg were discussed, but how Gbg-binding translates into alterations in functional activity of downstream targets has also been investigated by multiple laboratories. Two general mechanisms for effector regulation by Gbg depend on whether the target is cytosolic or membrane bound. In the case of cytosolic proteins such as PLCb2 or GRK2, whose substrates are localized to the plasma membrane, a potential mechanism for activation is recruitment to the plasma membrane by membrane-bound Gbg. For other targets, such as adenylyl cyclases or GIRK channels, that are transmembrane proteins, regulation must occur through conformational alteration. While many effectors are activated by Gbg, the potential mechanisms for regulation of each of these 2200 A. V. Smrcka G protein bg subunits are too numerous to be discussed here. GRK2 and GIRK regulation will be discussed briefly because mechanisms of activation of GRK2 and GIRK have been well studied and represent examples of either translocation-based or allosteric regulation. The mechanism for activation of PLCb by Gbg is less clear and may, in fact, be regulated by both translocation and allosteric regulation, as will be discussed in greater detail.
Activation of GRK2 by Gbg
An example of an enzyme whose activity is regulated by Gbg-dependent translocation is GRK2. GRK2 is normally cytoplasmic and there is strong evidence that, during receptor activation, free Gbg subunits are released that provide a binding site for GRK2. In cooperation with phosphatidylinositol 4,5 bisphosphate (PIP 2 ), Gbg subunits recruit GRK2 to the membrane, where it can interact with and phosphorylate activated GPCRs [112] . In addition to its role in membrane recruitment, Gbg could allosterically modulate GRK2 function. Complexes between Gbg and GRK2 have been crystallized and the structures solved [15, 96] . Since the GRK2 structure in the absence of Gbg was not solved, it could not be determined whether Gbg-binding alters the structure of GRK2. Biochemical analyses suggest subtle rearrangements of the GRK2 structure upon Gbg-binding, but the functional significance of these alterations are not clear [97] .
Activation of GIRK channels by Gbg
In the case of all membrane bound proteins such as ion channels and adenylyl cyclases the activation mechanism requires structural alterations rather than translocation. No direct structural data yet exists that demonstrates specific alterations of effector conformation upon Gbg binding. For Gbg-dependent regulation of GIRK, a combination of mutagenic analysis, biophysical studies of channel properties, and homology modeling based on a bacterial voltage-dependent K + channel, have been used to develop a proposed mechanism for Gbg-dependent activation. The model suggests that Gbg binding to an intracellular soluble domain of the channel strengthens interactions between the channel and PIP 2 and alters the position of a helix at the mouth of the conductance pore to increase the activity of the channel [113, 114] . For this and other targets the details of conformational changes that occur upon Gbg binding are unknown and await detailed atomic level structural determination of an effector with and without bound Gbg.
Activation of PLCb by G protein bg subunits
Two independent analyses examined whether translocation is necessary for Gbg-dependent activation of PLC activity. Both found that PLCb has an intrinsic capacity to bind to membrane surfaces that is independent of interactions with Gbg subunits [115, 116] . In these experiments, Gbg subunits did not alter the proportion of PLC associated with membrane surface but, at the same time, increased PLC activity. This indicates that one mechanism for activation of PLC isoforms is to alter its enzymatic activity either through conformational alteration of the active site or modulating the orientation of PLC with respect to the membrane surface. Key to understanding how Gbg activates PLC that is bound at the membrane is to understand the mode of interaction of Gbg with PLC. Structures of PLCd1 and PLCb2 have been solved that provide a detailed picture of the domain organization of these enzymes , when the Ga switch II Gb interface opens AGS8 binds, but since AGS8 can bind to Ga and Gb, the bivalent interaction of Ga with the complex is maintained and subunit dissociation does not occur.
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Vol. 65, 2008 Review Article 2201 ( Fig. 5A and B) [117, 118] . PLCd and PLCb2 share very similar domain structures. Both contain an Nterminal pleckstrin homology domain followed by an EF hand domain, conserved X and Y domains that comprise the catalytic domain and a C2 lipid binding domain. In PLCb2 the C2 domain is followed by an extended C-terminal domain that interacts with Ga q GTP. The PH domain of PLCd was deleted in the expressed protein used to solve the PLCd structure and the C-terminal extension beyond the C2 domain was removed in the protein used to solve the PLCb2 structure. Early biochemical studies indicated that deletion of the PLCb2 C-terminus eliminates regulation by Ga q without affecting Gbg-dependent regulation [119] . While a structure has been solved for a Rac-PLCb2 complex, no structural data exists as yet for the Gbg/PLCb complex. On the other hand, biochemical approaches have yielded information about the nature of Gbg-PLC interactions. Two sites for interaction of Gbg on PLCb2 have been proposed, one on the catalytic domain and one on the PH domain. Here, the data supporting these two sites will be presented and the implications with respect to regulation of PLC enzymatic activity by Gbg will be discussed.
The first evidence that the catalytic domain could interact with Gbg came from a screen of fragments of PLCb2 for their ability to compete for PLCb2 activation by Gbg in transfected tissue culture cells [101] . Two overlapping fragments from the catalytic Y domain of PLC blocked activation by Gbg or a G i coupled C5A receptor but not the G q coupled a 1 -adrenergic receptor. A GST fusion protein comprising a portion of one of these fragments, L580-V641 within the conserved Y domain, bound directly to purified Gbg in vitro, demonstrating a direct interaction between the catalytic domain of PLCb2 and Gbg. To further narrow down the interaction region, examination of a homology model of PLCb2 based on the structure of PLCd identified surface exposed regions likely to be accessible to Gbg [102] . Overlapping peptide fragments corresponding to these exposed regions were synthesized and shown to inhibit Gbgdependent activation of PLCb2 in a purified system leading to identification of E574-K583 as a Gbg binding region on PLCb2 (Fig. 5B , light blue helix). Direct interaction of these peptides from the PLCb2 catalytic domain with Gbg was confirmed by chemical crosslinking to both Gb and Gg in a manner that was competed with excess PLCb2 or PLCb3 holoenzyme [102] . To confirm that this region was important for PLCb2 activation in the context of the PLCb2 holoenzyme, triple alanine substitutions in the PLCb2 E574-K583 helix inhibited activation of PLCb2 by Gbg subunits with minimal effects on PLC basal enzymatic activity [103] . Finally, triple alanine mutation of E574, L575 and K576 disrupted direct binding of purified PLCb2 to Gbg [120] . Together, these data strongly suggest that this region of the catalytic domain is involved in direct interactions with the Gbg subunit and that interaction of Gbg with these amino acids regulates PLCb2 activity.
In support of the idea that the pleckstrin homology domain confers binding and activation by Gbg is the observation that the isolated PH domain from PLCb2 interacts with Gbg on membrane surfaces as detected by fluorescence resonance energy transfer [121] . A second key observation is that splicing of the PLCb2 PH domain onto PLCd confers the ability of PLCd to be activated by G protein bg subunits [122] . This chimeric PLC bound to lipid membranes with properties similar to PLCb2, suggesting the activation involved conformational activation rather than membrane translocation. Point mutations in the PH domain of the chimera inhibited Gbg-dependent activation. On the other hand, in chimeras of PLCb2 with the PH domain of PLCb1, there is no substantial loss in activation of the enzyme by Gbg despite the fact that PLCb1 is not activated by Gbg [123] . This suggests that domains other than the PH domain are required for activation of PLC by Gbg, consistent with the observed binding of Gbg to the catalytic domain. How might Gbg binding to the PH domain or the catalytic domain of PLC alter enzymatic activity, since (Fig. 5B ). This suggests a potential mechanism for activation that involves removal of this inhibitory linker from the active site [124] . Since the linker still occludes the active site in the RacGTP-bound PLCb2 co-structure, the investigators propose that Rac causes alterations in interactions of the active site with charged lipids in the membrane that lead to displacement from the active site. Overall, the inhibitory linker model could allow for multiple modes of protein binding to achieve increases in enzyme activity. These could involve reorientation of PLC at the membrane that would allow negatively charged lipid head groups to pull this domain from the active site, for proteins to bind directly to this region, or for proteins to bind at a distance to cause conformational alterations that relieve this constraint. Scarlata and colleagues propose that binding of Gbg to the PH domain alters the orientation of the PH domain relative to the catalytic domain, allowing the catalytic domain to productively interact with the substrate at the membrane surface [125, 126] . In favor of this hypothesis, measurements of interdomain movements of a PLCd/PLCb chimera by FRET indicate that Gbg causes alterations in interactions between the catalytic domain and the PH domain. This mechanism could be operating as an independent mechanism for PLC activation or it could work in concert with direct binding of Gbg to the catalytic domain. Binding of Gbg at the catalytic domain, or the PH domain, could alter interactions of the catalytic domain with the membrane that would relieve autoinhibition or could cause displacement of the linker through conformational alterations in the protein.
Further biochemical and structural analysis will be required to determine the validity of these proposed mechanisms.
Receptor-independent mechanisms for activation of G protein signaling through Gbg
An emerging area is non-receptor and nucleotide exchange-independent mechanisms for G protein activation [7, 127] . Some of these mechanisms involve binding of proteins to Ga subunits leading to release of free Gbg subunits, but other proteins and peptides have been recently found that activate G protein bg subunit signaling through direct binding to Gbg. Since Gbg is not thought to undergo conformational changes that could lead to nucleotide exchange on Ga or result in subunit dissociation, the mechanisms for action of these molecules that bind directly to Gbg are not obvious. In most cases, detailed studies of these mechanism have not been done, but some examples are discussed that shed new light on potential roles of Gbg in G protein activation are discussed below.
Activation of Gbg signaling by Gbg binding peptides SIRK/SIGK
An instructive study is based on the observation that some of the peptides identified through phage display screening that bind to the Gbg "hot spot" cause activation of G protein dependent signaling pathways in cells. SIRK peptide was discovered in a the phage display screen using G protein bg subunits as a target for binding [107] . Despite being discovered in a naïve random peptide screen, the peptide bound to a biologically relevant signaling surface, as demonstrated by its ability to block Gbg -dependent PLCb2 and PI3Kg activation in vitro. It did not affect Gbgdependent inhibition of adenylyl cyclase in vitro or inhibition of N-type Ca 2+ channels in SCG neurons, demonstrating selectivity for inhibition of some Gbg targets. A surprise came when studying the effects of cell-permeable versions (either tat-modified or myristoylated versions) of SIRK (mSIRK or tatSIRK) and a related peptide SIGK in intact cells. These peptides, predicted to inhibit G protein signaling, rapidly, potently and effectively activated the ERK/MAP kinase pathway in intact cells in a Gbg-dependent manner [128] . To confirm that Gbg was the target of these peptides in intact cells, the effects of mSIRK on CHO cells, transfected with mutant Gb(bW332A), which does not bind the peptide, were examined. In these cells, with strong constitutive expression of Gb(W332A) and Gg 2 , the expressed subunits appear to substitute for a significant proportion of the endogenous Gbg complexes, and substantially inhibit mSIRK dependent ERK activation [129] . This strongly supports the idea that mSIRK activates Gbg subunit signaling in intact cells by binding directly to Gbg subunits. To explain this observation it was proposed that the peptide must be binding to Gbg in a way that Cell. Mol. Life Sci.
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To understand the mechanism of action of these peptides their effects on Ga/bg interactions were examined. Kinetic and equilibrium analysis indicated that SIRK and SIGK enhanced the rate of G protein subunit dissociation in the presence of excess GDP and the absence of GTP [10, 128] . Additionally, other peptides known to bind to Gbg and compete for Ga subunit interactions did not influence Ga subunit dissociation kinetics. This argues that the basis for the effect is not a strict competition for Gabg subunit interactions, since this would be expected to alter equilibrium binding without affecting dissociation kinetics of a preformed complex. The solved structure of SIGK peptide/Gbg complex showed SIGK bound to the Ga subunit switch II-binding region on Gbg [111] (See Fig. 1C and Fig. 6 ). This suggests that SIGK/SIRK should directly compete for Ga binding to Gbg. A proposed model for how Gbg could enhance subunit dissociation that can explain most of the data is depicted in figure 4B . As described previously, the Ga/bg switch II interface is in a dynamic state of association and dissociation ("breathing") while overall Gbg/a interactions are maintained by the Ga N-terminal helix. We propose that SIRK/SIGK can insert into this interface during this transient breathing and block this part of the Gbg/ a interaction. The resulting dissociation rate would then only be limited by the off rate for the weakly interacting N-terminal a helix, leading to rapid subunit dissociation. This model fits much of the data and provides supporting evidence that this surface "breathes". On the other hand, the model predicts that any peptide that binds at this interface and competes for Ga/bg interactions in an equilibrium experiment should enhance subunit dissociation, which is not what is observed. This discrepancy suggests the effects of the peptide involve a mechanism other than simple competition [10, 111] . Such a mechanism remains to be established.
Overall, these studies highlight a novel potential mechanism for G protein activation that could be exploited physiologically by receptors, by Activators of G protein signaling (AGS proteins), or pharmacologically. AGS proteins. Activators of G protein signaling (AGS proteins) are a group of structurally distinct proteins discovered in a yeast-based screen for activation of the Gbg dependent pheromone response pathway [4, 7, 127] . The mechanisms for G protein activation by proteins that bind Ga subunits (Class I and Class II AGS proteins) are simple to understand. For example, Class I AGS proteins include DexRas and promote nucleotide exchange on Ga subunits, releasing free Gbg through a mechanism similar to receptors. Class II AGS proteins contain a GPR or Goloco motif that binds to Ga i/o family subunits and promotes Gbg subunit dissociation through a nucleotide exchangeindependent mechanism leading to accumulation of free Gbg subunits that can activate downstream targets. The GPR/Goloco motif in these proteins binds to the switch II region of the Ga subunit near the interface between Ga and Gbg subunits [130] . This results in a conformational change in switch II at the Ga/bg interface, disrupting Ga/bg interactions and leading to subunit dissociation. Class III AGS proteins that bind directly to Gbg are less well investigated or understood. Since Gbg is not thought to undergo significant conformational alterations, it is difficult to imagine a mechanism that does not involve binding of the AGS protein to the Ga/bg interface. But if the AGS protein bound to the region on Gbg at the Ga/bg interface, it would obscure this critical signaling surface on Gbg required for activation of target proteins. Thus a conundrum is presented where somehow these activating proteins that bind the Gbg subunits must relieve the constraints of the GDP bound heterotrimer yet still allow Gbg to signal downstream. Some insight into the mechanism of action of these proteins comes from a recent analysis of AGS8. AGS8 was found in the yeast-based screen using a cDNA 2204 A. V. Smrcka G protein bg subunits library derived from a rat model of transient cardiac ischemia. AGS8 binds to Gbg subunits but does not significantly affect Gbg-dependent PLCb2 activation when Gbg is transfected into COS cells in the absence of Ga subunits [131] . However, AGS8 relieves the inhibition of PLC seen when Ga subunits are transfected with Gbg subunits and Gbg-dependent PLC activation is inhibited due to formation of the heterotrimer. The AGS8 binding site on the G protein bg subunit appears to reside at the Ga/Gbg interface at a site that overlaps with the SIGK binding site. This observation was puzzling since AGS8 did not block PLC activation, yet amino acids at the SIGK binding surface are required for PLC activation. Another surprise is that AGS8 does not promote subunit dissociation or block Ga i1 subunit binding to Gbg. These observations are difficult to reconcile with the SIGK data demonstrating that peptide binding at this site led to dissociation of Ga from Gbg, until it was found that AGS8 could also bind to the Ga i1 subunit in a nucleotide-independent manner. SIGK promotes subunit dissociation by binding at the Ga/Gbg interface but binds only to Gbg, so Ga subunits are released. AGS8 binds both Ga and Gbg resulting in retention of Ga subunit binding in the complex (Fig. 4C) . Thus, AGS8 binds to the G protein heterotrimer by binding the Gbg and Ga subunits simultaneously and does not cause dissociation of these subunits, yet it activates PLCb2 signaling by a GaGDPbg heterotrimer.
In this AGS8/Ga/Gbg complex, the mechanism by which Gbg could activate PLCb2 is not easily explained based on our current understanding of regulation of Gbg-dependent signal transduction. A critical Gbg surface for signaling to PLCb2 activation is bound to AGS8. In our model, when AGS8 binds to the "hot spot" and forms a signaling complex with Ga and Gbg subunits, the PLCb2 inhibitory site at the amino terminus becomes a stimulatory binding site. This PLCb2 binding site was previously identified as an inhibitory site by chemical crosslinking and mutagenesis [103] (discussed in section 7). This implies that AGS8 alters Gbg conformation or orientation at the membrane to make the bound complex competent for downstream signaling. An alternative model is that AGS8 itself provides binding determinants for PLC binding in conjunction with amino acids at the Gbg Nterminus that participate in PLC activation. More direct evidence to address these ideas awaits further structural investigation. These two examples (SIGK and AGS8) of Gbgdependent, nucleotide exchange-independent, signaling mechanisms suggest additional modes of G protein activation outside of the well defined classical paradigm for G protein activation. How these biochemically characterized mechanisms operate in a physiological context remains to be determined. With emerging evidence that receptors bind directly to G protein bg subunits these observations may also be relevant to GPCR signaling. It is possible that some receptors, in addition to causing nucleotide exchange, can also promote subunit dissociation that is mechanistically independent of the nucleotide exchange process on Ga subunits. On the other hand there is increasing evidence that under some GPCR-dependent G protein activation conditions the subunits may not dissociate [5, 6, 132 ]. The molecular model described for the action of AGS8 suggests potential mechanisms for non-dissociated G protein signaling complexes to promote downstream signaling. Overall, it is clear that the current simple picture of Gbg as a passive participant in the G protein activation and signaling process needs revision.
NDPK phosphorylation of Gbg G protein b subunits have been found to be substrates for phosphorylation in a variety of tissues [133, 134] . A model has been developed where transient highenergy phosphorylation of a histidine residue serves as a phosphate donor involved in transfer of phosphate from the Gb subunit to GDP associated with Ga subunits leading to activation of the Ga subunit and subsequent signaling in a GPCR-independent manner. The amino acid phosphorylated in Gb is His 266, and requires nucleotide diphospho (NDP) kinase. Direct reconstitution of phosphorylation with purified NDP kinase has not been achieved, suggesting a requirement for an additional cofactor in the reaction. The significance of this process was unclear until a recent study in cardiac myocytes suggested a role in regulation of cAMP levels [135] . In these studies a Gb 1 His 266 Leu mutant was transduced into neonatal or adult cardiac myocytes where the mutant is functionally incorporated into endogenous heterotrimers replacing the endogenous subunits. Basal cAMP levels were reduced in both neonatal and adult cardiac myocytes in cells transduced with Gb 1 His 266 L compared to cells transduced with wild type Gb 1 . Interestingly, baseline contractility was reduced by this mutant in adult myocytes without any affect on stimulation by a b-adrenergic receptor agonist. These data suggest that, in a physiological system, this receptor-independent signaling mechanism that relies on transient phosphorylation of Gb, regulates baseline cAMP levels and contractility in the heart.
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Physiological significance of Gbg activation G protein bg subunit-mediated activation of effectors has diverse roles in regulating of cell physiology. In excitable cells, Gbg subunits released from G i modulate membrane potential through activation of K + channels and inhibition of voltage gated Ca 2+ channels. In neurons this suppresses excitability and inhibits neurotransmitter release. In atrial myocytes vagal release of acetylcholine suppresses heart rate through Gbg-dependent activation of K + channels [74] . In migrating immune cells, chemokine receptors, such as the IL-8 receptor or CXCR4, are coupled to the release of Gbg subunits from G i [136, 137] that is critical for mediating directional chemotaxis as well as release of superoxide and other inflammatory mediators. Several mouse knockout studies implicate Gbgregulated effectors in various physiological functions; For example, in mice lacking Gbg-regulated PLCb3, morphine acting at G i linked opioid receptors produced painkilling effects at much lower doses [138] . Genetic deletion of Gbg-regulated PI3Kg resulted in decreased neutrophil migration and a reduction in inflammation [139, 140] .
Activation of multiple G i and G q -coupled receptors, including thrombin, lysophosphatidic acid (LPA), and acetylcholine receptors, results in a mitogenic response in several cell types. MAP kinases are critical components in the growth-promoting pathways regulated by these receptors. Gbg subunits indirectly activate MAP kinase, suggesting that Gbg subunits may mediate the growth-promoting effects of many G protein-coupled receptors [141, 142] . Sequestering Gbg in smooth muscle cells inhibits serum stimulated growth and vascular restenosis [143] .
G Protein bg subunits as a target for therapeutic development The diverse functionality of Gbg signaling in cellular physiology suggests that manipulating Gbg function could have significant therapeutic potential. On the other hand Gbg is known to be required for G protein activation by all G protein coupled receptors, so blocking all Gbg functions would be predicted to have side effects. The potential therapeutic usefulness of targeting Gbg signaling has been investigated extensively using the carboxy terminus of GRK2 (GRK2ct) [143 -147] and, to a lesser extent, with other Gbg binding peptides such as QEHA [148] . GRK2ct, despite binding at the Ga/bg "hot spot" interface, interferes with Gbg signaling to downstream targets without disrupting GPCR dependent G protein activation in general. The basis for this selectivity is unclear. This has strong implications for small molecule development, indicating that a strategy that targets the Ga/bg interface "hot spot" could successfully block downstream Gbg signaling without disrupting G protein signaling in general.
Gbg and heart failure. One well studied example where GRK2ct has been used to demonstrate the therapeutic potential of targeting Gbg is in cardiac function and failure. One of the characteristics of heart failure is the loss of b-adrenergic receptor (bAR)-dependent cardiac reserve. A prominent hypothesis is that the underlying mechanism involves an increase in the activity of GRK2, a kinase that phosphorylates and desensitizes the bAR as well as other GPCRs. During progression to heart failure, chronically elevated catecholamine levels lead to chronic stimulation of bAR resulting in chronic desensitization of the receptor by GRK2. GRK2 activity is controlled by Gbg which, upon GPCR activation, is released and recruits GRK2 to the receptor, leading to its phosphorylation and desensitization. GRK2ct blocks this recruitment and enhances bAR function. A seminal study indicating successful application of this strategy was the demonstration that transgenic cardiac over-expression of GRK2ct in mice increased cardiac performance in response to bAR stimulation [147] . Later, it was demonstrated that cardiac over-expression of GRK2ct in murine models of heart failure dramatically rescued cardiac function [146] and expression of GRK2ct in cardiac myocytes isolated from biopsies of human heart failure patients significantly improved contractile function [149] . These and a plethora of other studies have shown the value of blocking Gbg signaling function in improving cardiac functions in disease [145] .
Gbg and inflammation. Chemokines and chemokine receptors have been the subject of anti-inflammatory pharmaceutical development [150 -156] . A potential problem is the overwhelming complexity of these signaling molecules (multiple chemokines, chemokine receptors, and redundancy) making it difficult to know which specific receptors to target for conditions such as arthritis. Polychemokine [157] or combinations of different chemokine [158] antagonists have been suggested, but there may be chemokines that act as an agonist at one receptor and an antagonist at another [159] . Of recent interest is the demonstration that deletion of PI3Kg in mice inhibits neutrophil migration in response to chemoattractants and inhibits inflammation. PI3Kg activity is directly regulated by Gbg released from chemokine and chemotactic peptide receptors and is relatively selectively expressed in monocytic cells, suggesting that blocking 2206 A. V. Smrcka G protein bg subunits Gbg-regulation of PI3Kg could be an effective strategy for treating inflammatory diseases that may overcome the necessity to target mutliple chemokine receptors [139] . In a related study it was demonstrated that deletion of PI3Kg protected apoE -/-mice from development of atherosclerosis, potentially through disabling macrophage migration and inflammatory functions [160] . An alternate approach that is currently being investigated is specific pharmacological targeting of PI3K catalytic activity with inhibitors that are relatively selective for PI3Kg relative to other PI3K isoforms [161] . In this approach blocking PI3Kg would circumvent the problems associated with chemokine receptor redundancy by blocking a common signaling target of chemokines. An alternate approach may be to inhibit Gbg-dependent activation of PI3Kg, which would selectively block PI3Kg relative to other PI3K isoforms since these isoforms are not regulated primarily by Gbg. These are just two of multiple examples where Gbg binding proteins or peptides have been used to demonstrate the involvement of Gbg in pathology and disease and where inhibition of Gbg with these agents has ameliorated the pathology. Other examples include vascular restenosis [143] , drug addiction [162] and prostate cancer [144] .
Small Molecule Targeting of Gbg
Screening the NCI diversity library against the "hot spot" Given that Gbg may be a suitable target for therapeutic development, our laboratory screened for small molecules that could be used in vivo to inhibit Gbg signaling. The "hot spot" was targeted because this is a major site of protein-protein interactions and our studies with peptides suggested that differential modulation of G protein signaling functions could be accomplished by binding to this site. In this screen a number of molecules that bound to the "hot spot" were identified based on the ability to compete with SIGK binding and bound with IC 50 values ranging from 0.2 to 50 mM [107] . More recently direct binding of M119 and a related molecule, gallein, to Gbg was examined by surface plasmon resonance [163] . In the SPR assay, gallein bound to immobilized Gbg with an apparent K d that was similar to the IC 50 value obtained for M119-or gallein-dependent inhibition of SIGK binding. Structurally related molecules that did not compete for SIGK peptide binding did not bind in the SPR assay, confirming the specificity of the SPR assay for active compound binding.
Protein-protein interactions
While the compounds identified in the screen inhibited interactions between Gb 1 g 2 and the peptide SIGK, it is thought to be relatively difficult for small compounds to disrupt true protein-protein interactions. Thus, selected compounds were tested for their ability to disrupt protein interactions with bona fide Gbg binding partners: Ga i1 and effectors. The overall Ga i1 -bg interaction surface spans 1800 2 [11, 12] and the dissociation constant (K d ) for Ga i1 binding to Gbg is approximately 1 nM [164] . One compound, M119, potently inhibited Ga i1 binding to Gb 1 g 2 . M119 and other compounds inhibited binding of effector molecules to Gbg both in direct binding assays and in functional reconstitution experiments. Based on the selectivity of phage displayed peptides that bound to the "hot spot", and the idea that each target has a unique "foot print" on the Gbg surface, it was predicted that different small molecules, binding in different ways to the "hot spot", would have distinct effects on individual Gbg-target interactions. Initial support for this idea came from comparative analysis of M119 and M201 with respect to target interactions. While both compounds were able to compete for Gbg-GRK2 interactions with similar potency, M119, and not M201, blocked Gbg-dependent activation of PLCb2 in vitro. This indicates that both compounds can bind to Gbg but have differential effects on Gbg protein-protein interactions. Other compounds also have similar selectivity characteristics (unpublished data).
Analysis of compound efficacy and selectivity in intact cells
Based on the biochemical selectivities described in the previous section, it would be predicted that the compounds should be able to differentially modulate Gbg-dependent signaling processes downstream of GPCRs. This was tested in neutrophils where Gbg mediates signaling responses to chemoattractants and chemokines that are responsible for directing chemotactic migration and superoxide production involved in inflammatory responses. The pathways regulated in these cells include activation of PI3-kinase g, PLC activation, ERK1/2 activation and GRK2 regulation. Compounds that inhibited Gbg-dependent PLC and PI3-kinase activation in vitro were able to inhibit these pathways in neutrophils in response to chemoattractants. These compounds did not block activation of ERK1/2 by fMLP, indicating that GPCR signaling was intact and demonstrating a level of selectivity of the compounds for G protein bg subunit signaling in intact cells. Compounds shown to be selective for particular pathways in vitro displayed similar characteristics in cells. M201, for example, blocked GRK2 recruitment Cell. Mol. Life Sci.
Vol. 65, 2008 Review Article 2207 but did not affect Gbg-dependent PLC activation, while M119 was able to inhibit both, consistent with their in vitro properties.
In vivo evaluation of small molecules Based on the discussion of therapeutic relevance it would be predicted that compounds that inhibit Gbg signaling would have predictable and potentially beneficial effects in vivo. Some areas with clear potential include heart failure and inflammation. As discussed earlier, knockout of PLCb3 leads to increased potency of morpine-dependent analgesia. Since PLCb3 is regulated by Gbg, one would predict that Gbg-blocking compounds, if introduced into analgesic centers in the brain, would have similar effects.
PLCb3 and Opioid-dependent antinociception: Coadministration of M119 with morphine intracerebroventricularly (i.c.v) resulted in an 11-fold increase in the analgesic potency of morphine, whereas administration of M119 alone had no effect on antinociception. Importantly, M119 also had no effect on morphine-dependent antinociception in PLCb3 -/-mice. Gbg may block interactions with PLCb3 but not Ga or other effectors such as K + or Ca 2+ channels critical for the actions of opioid agonists [165] . If M119 were globally blocking Gbg subunit functions, morphineinduced antinociception would have been attenuated rather than potentiated with M119 co-administration. These data highlight the specificity of M119 actions and the selective nature of M119 both in vitro and in vivo.
Neutrophil Chemotaxis and inflammation: As discussed, Gbg-dependent activation of PI3kg in neutrophils is important in directing neutrophil migration in response to chemoattractants. Activation of this receptor system leads to a gradient of PIP 3 production with enhanced accumulation at the leading edge of the cell that is important for polarizing the cells in the direction of the chemo-attractant [166, 167] . In animal models of neutrophil chemotaxis, deletion of PI3Kg results in defects in neutrophil accumulation and reduced inflammation [139, 140] . Since PI3Kg and other molecules important for chemoattractant-dependent chemotaxis are activated by Gbg, M119 and the related molecule, gallein were tested for their ability to inhibit chemoattractant-dependent neutrophil migration [163] . M119 and gallein significantly blunted fMLP-, but not Gbg-independent GM-CSFdependent, neutrophil migration, supporting the idea that blocking Gbg-dependent signaling in neutrophils inhibits migration. Consistent with this data, gallein inhibited inflammation in a whole animal model of inflammatory processes. In a carrageenan-induced footpad inflammation assay, intraperitoneal and oral administration of gallein inhibited inflammatory responses with a potency similar to a cyclo-oxygenase inhibitor, indomethacin. Thus, inhibiting Gbg signaling with small molecules could be a novel approach to treat inflammation.
Basis for Gbg targeting and selectivity by small molecules Molecules were found that bound to Gbg and selectively inhibited Gbg protein-protein interactions in a limited screen of a small set of organic molecules. Two readily apparent questions that arise are: 1) What is the molecular basis for small molecule selectivity and, 2) what are the properties of the Gbg "hot spot" that allow it to bind to small molecules with relatively high affinity? With regard to the first question, one hypothesis is that small molecule selectivity is based on differential spatial occupancy of the "hot spot". The basic premise as discussed in section 7 is that different Gbg targets interact with the "hot spot" utilizing different subsets of amino acids on Gb for binding. If the small molecules occupy different spatial regions of the hot spot and the basis for their effects is steric occlusion of effector interactions, the prediction is that the compounds would have distinct effector inhibition profiles based on where they bound in the "hot spot". An alternate hypothesis is that the chemistries of the compounds, rather than steric effects, alter target binding. For example, a compound containing a carboxylic acid moiety could introduce a negative charge at the surface that could differentially alter effector binding. Currently, direct evidence in support of either of these hypotheses is lacking, but identification of the binding modes for each compound, either by mutagenesis or structural methods, should provide some illumination. A prevalent idea is that finding small molecules that bind at protein interaction surfaces to disrupt proteinprotein interactions is difficult. In contrast either to active sites of enzymes or cell surface receptors, protein-protein interaction surfaces have been thought to be generally flat and may not have a clearly defined three dimensional binding pocket that can support the multiple interactions in three dimensions that are likely required for high affinity binding of a small molecule to a protein [168, 169] . A second issue is that protein interfaces are generally large, often greater than 1500 2 , suggesting that occupation of a small portion of this surface with a small molecule might not disrupt enough of the binding energy to disrupt the interaction. Increasingly, however, examples of small molecules that bind to crevasses in 2208 A. V. Smrcka G protein bg subunits protein interaction surfaces and disrupt protein-protein interactions are emerging [170] . In the case of Gbg, because of the hole in the middle of the bpropeller, the protein-protein interaction surface is concave rather than flat, providing 3-dimensionality to the surface that may provide more binding interactions for small molecules. This interaction surface is also a "hot spot", as previously discussed, that contributes a large portion of the binding energy for Gbg-target interactions. Thus, binding of small molecules to this surface would be predicted to disrupt this critical binding site and inhibit interactions between Gbg and its effectors. This combination of having a good binding site for small molecules overlapping with a critical protein interaction surface may not be coincidental and could reflect the inherent "binding" capability of this site.
Concluding remarks
G protein bg subunits are central participants in G protein signaling, scaffolding receptors, G protein a subunits, and effectors. As investigations of this protein continue to move forward, its importance in a myriad of physiological functions is increasingly appreciated. Despite years of investigations by many investigators, novel and interesting properties, mechanisms and functions for these proteins continue to emerge, and this will likely continue. Some of the major questions still remaining concern how signaling specificity is maintained with such a promiscuous signaling protein and what is the molecular significance of the very large isoform diversity of these Gbg combinations. Given the biological potential of these proteins as therapeutic targets, answering these questions could contribute significantly to development of novel pharmacologic approaches to therapeutics for a number of important diseases.
